Further studies elucidating the mechanism of tumor evasion from CTL cytotoxicity and the development of appropriate protocols for TLR3 adjuvant therapy would prove useful in this field to allow for complete tumor regression in cancer patients. The gene discussed is TLR3; the disease is neoplasm.